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Abstract
Summary An earlier systematic review on interventions to improve adherence and persistence was updated. Fifteen studies
investigating the effectiveness of patient education, drug regimen, monitoring and supervision, and interdisciplinary collabora-
tion as a single or multi-component intervention were appraised. Multicomponent interventions with active patient involvement
were more effective.
Introduction This study was conducted to update a systematic literature review on interventions to improve adherence to anti-
osteoporosis medications.
Methods A systematic literature review was carried out in Medline (using PubMed), Embase (using Ovid), Cochrane Library,
Current Controlled Trials, ClinicalTrials.gov, NHS Centre for Review and Dissemination, CINHAL, and PsycINFO to search for
original studies that assessed interventions to improve adherence (comprising initiation, implementation, and discontinuation)
and persistence to anti-osteoporosis medications among patients with osteoporosis, published between July 2012 and December
2018. Quality of included studies was assessed.
Results Of 585 studies initially identified, 15 studies fulfilled the inclusion criteria of which 12were randomized controlled trials.
Interventions were classified as (1) patient education (n = 9), (2) drug regimen (n = 3), (3) monitoring and supervision (n = 2), and
(4) interdisciplinary collaboration (n = 1). In most subtypes of interventions, mixed results on adherence (and persistence) were
found. Multicomponent interventions based on patient education and counseling were the most effective interventions when
aiming to increase adherence and/or persistence to osteoporosis medications.
Conclusion This updated review suggests that patient education, monitoring and supervision, change in drug regimen, and
interdisciplinary collaboration have mixed results on medication adherence and persistence, with more positive effects for
multicomponent interventions with active patient involvement. Compared with the previous review, a shift towards more patient
involvement, counseling and shared decision-making, was seen, suggesting that individualized solutions, based on collaboration
between the patient and the healthcare provider, are needed to improve adherence and persistence to osteoporosis medications.
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Introduction
Osteoporosis remains a major health problem worldwide
influencing patient’s health-related quality of life, mortality,
and representing a substantial economic burden on society.
The burden of osteoporosis is further expected to increase as
a result of the aging population [1, 2]. Osteoporosis medica-
tions have shown to be effective in fracture risk reduction [3];
however, it is well known that adherence to osteoporosis med-
ications is poor and suboptimal, varying from 34 to 75% in the
first year of treatment [4, 5]. Persistence levels at 1 year were
estimated between 18 and 75% [6]. This suboptimal adher-
ence and persistence leads to increased fracture rate (up to
30%) and worse health outcomes (more subsequent fractures,
lower quality of life, and higher mortality), substantially dete-
riorating the cost-effectiveness resulting from these medica-
tions [7, 8].
Improving adherence to osteoporosis medications is there-
fore needed but this remains a challenging task. Many factors
of non-adherence and non-persistence to osteoporosis medi-
cations have been identified such as older age, polypharmacy,
side effects, and lack of patient education. Reasons for non-
adherence are thus numerous and multidimensional, varying
for each patient [9]. Several interventions and programs have
therefore been developed to improve osteoporosis medica-
tions adherence. A previous systematic literature review
(SLR) published in 2012 noted several promising interven-
tions to improve osteoporosis medication adherence and per-
sistence, such as drug regimen and patient support, automatic
electronic prescription, and pharmacist intervention [10]. This
SLR, limited to articles published up to June 2012, further
revealed a limited number of studies, the lack of rigorous
evaluation of clinical effectiveness, and therefore the need
for further studies [10].
Since this SLR, theories and practical experience on adher-
ence and adherence interventions have evolved [11].
Moreove r, t he me thodo log i ca l qua l i t y o f non-
pharmacological interventions has overall improved. This, to-
gether with continuing low adherence to anti-osteoporosis
medications [12], the frequent access to the previous SLR,
and the publications of several new adherence interventions
preceding this study, justifies an update [10].
For this updated review, it was aimed to appraise studies
concerning interventions to improve adherence and persis-
tence to medications for osteoporosis patients in primary of
secondary care, published between July 2012 and December
2018.
Methods
This systematic review was executed in accordance with the
PRISMA statement and with the use of a review protocol [13,
14]. The protocol for this systematic review was registered in
PROSPERO (unique ID number: 97472, available on https://
www.crd.york.ac.uk/prospero/).
Search strategy
With the help of an expert library specialist, a comprehensive
systematic literature search was designed and performed in
Medline (using PubMed), Embase (using Ovid), Cochrane
Library, Current Controlled Trials, ClinicalTrials.gov, NHS
Centre for Review and Dissemination, CINHAL, and
PsycINFO. Reference list of identified articles were then
manually searched, and forward reference searching was
conducted in Web of Science. Detailed search strategies can
be found in Appendix 1.
Selection criteria
Articles were included if they met the following eligibility
criteria: (1) original study which assessed the effects of inter-
ventions aimed on improving adherence or persistence of os-
teoporosis medications, (2) publication date between July 1,
2012, and December 31, 2018 (the searchwas restricted to this
period to provide an update of the previously published SLR
[10]), and (3) available in English language. Conference pro-
ceedings were not included.
The selection of articles was performed in a standardized
manner in a three-step process. First, duplicate records were
deleted. Second, articles were analyzed by screening the title
and abstract (DC). In case of doubt, the article was included
for full-text review. Third, full texts were independently
reviewed on the eligibility criteria by two authors (DC and
SdK). If necessary, consensus was reached by both authors
through discussion with a third author (MH).
Definitions of adherence and persistence
Adherence and persistence to medications have been defined
differently in several ways [15]. For organizing data for this
review, the following ABC taxonomy, according to Vrijens
et al., was followed [16]. Medication adherence consists of
the three following quantifiable phases: (A) initiation (when
the patient takes the first dose of a prescribed medication), (B)
implementation (the extent to which a patient’s actual dosing
corresponds to the prescribed dosing regimen, from initiation
until the last dose), and (C) discontinuation (when the patient
stops taking the prescribed medication, for whatever rea-
son(s)). Persistence is defined as the length of time between
initiation and the last dose, which immediately precedes dis-
continuation [16].
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Extracted information
Data from the included studies were independently extracted
by two authors (DC and SdK) in a predesigned data abstrac-
tion sheet. A third author (LS) checked independently all ex-
tracted data. General information including author, year of
publication, country, and setting (primary care, secondary
care, or other) were first collected, then the intervention spe-
cialist (GP, medical specialist, pharmacist, or other), type of
study, population, sample size, outcome measurements (ad-
herence or persistence), type of intervention, and follow-up
time.
Type of interventions
Interventions extracted from data were classified into four
categories based on previous studies [10, 12]: (1) patient ed-
ucation (provision of information), (2) drug regimen, (3) mon-
itoring and supervision, and (4) interdisciplinary collabora-
tion. These interventions were frequently combined with pa-
tient counseling (advice and debate on provided information
focused on the individual patient). These modalities could be
administered as a single- or multicomponent intervention. In
this review, a multicomponent intervention halters two differ-
ent types of components, e.g., provision of educational mate-
rial and patient counseling, whereas a single component solely
uses one intervention.
Study quality
Risk of bias of the included studies was assessed by two re-
searchers (DC and SdK) with the Revised Cochrane risk-of-
bias tool for randomized trials (RoB 2) or the Risk Of Bias In
Non-randomized Studies - of Interventions (ROBINS-I) as-
sessment tool [17, 18]. To assess study quality, different qual-
ity appraisal tools were used specifically designed for each
type of study. For observational studies, the Strengthening
the Reporting of Observational Studies in Epidemiology
(STROBE) tool [19] was used. For clinical trials, the
Consolidated Standards of Reporting Trials (CONSORT) tool
[20] was used. Two researchers (DC and VW) independently
evaluated the selected studies. A third researcher (LS) ran-
domly checked four appraisals as additional check. All differ-
ences were resolved by consensus through discussion.
Synthesis of results
Due to the expected heterogeneity in the methods of adher-
ence measurement and of study outcomes, the analysis was




After deletion of duplicate records, our search resulted in 585
articles, of which 55 passed the abstract and title screening
(Fig. 1). After full-text assessment, 40 articles were excluded
because of the following reasons: no full text available (n = 8),
not specific for osteoporosis patients (n = 1), review article
(n = 2), lack of a medication adherence intervention (n = 22),
conference proceedings (n = 4), published before July 1, 2012
(n = 2), and methodologic article (n = 1), resulting in 15 arti-
cles. The PRISMA flow chart is presented in Fig. 1.
Study characteristics
The main study characteristics can be found in Table 1.
Twelve studies were randomized controlled trials (RCT)
[21–31] of which one was a cross-over RCT design [32].
Other studies were non-randomized, uncontrolled studies
[33–35]. A total of 162,804 patients were included, 155,803
in the intervention group and 7001 control patient [30, 35].
There was a large difference in sample sizes varying from 79
to 147,071 [28, 35]. Ninety-five percent of patients came from
two studies [24, 35]. Themajority of patients were female, and
eight studies included solely females [22, 25–28, 30, 32].
Seven studies were European [22, 26, 27, 30–33], five studies
North-American [24, 25, 29, 34, 35], two from Australia [21,
28], and one from Japan [23]. Follow-up time varied from 6 to
24 months [21, 28]. Interventions were executed in secondary
care (n = 13) [22–32, 34, 35], primary care (n = 1) [33], or in
both primary and secondary care (n = 1) [21]. Seven of the 15
interventions were conducted by either physicians and/or
nurses/nurse practitioners (n = 7) [21, 24, 26–28, 31, 34].
Other interventions were conducted by trained coordinators
(n = 1) [35], medical secretaries (n = 1) [22], pharmacists
(n = 1) [33], or a combination of physicians and allied
healthcare workers (n = 1) [36]. Four studies did not report
by whom the intervention was conducted [23, 25, 30, 32].
The studied interventions, inclusion and exclusion criteria,
and summarized outcomes can be found in Tables 2 and 3.
Definition and measures
Measures of adherence
Adherence to prescribed medication was mentioned as an out-
come in fourteen studies [21–25, 27–35]. Adherence was re-
ported as initiation (n = 1), implementation (n = 9), and dis-
continuation (n = 4). In two studies, the type of adherence
was not described [23, 24]. Initiation was described as initia-
tion of osteoporosis treatment by primary care physician
12 months after a fragility fracture [29]. Implementation was
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described as medication possession rate (MPR) ≥ 80% [21,
22, 28, 33, 35], a medication possession rate (MPR) ≥ 50%
[32, 35], per the instructions of the physician at regular inter-
vals and dosages [30], the percentage of the prescribed dose
taken [27], scoring ≥ 75% on the Morisky Medication
Adherence Scale (MMAS) [31], self-report of current osteo-
porosis medication use at 6 months [25], or active treatment
12 months after initiation [34]. Discontinuation was described
as continuing to receive treatment over the long term [30], as
permanently stopping anti-osteoporosis medication [33], con-
tinuation of treatment after 26 weeks [32], or continuing of
medication after 1 year [22]. Persistence was mentioned as an
outcome in three studies [26, 27, 31]. It was described as
taking medication 10 out of 12 months without medication
gaps longer than 2 weeks [27]. Two studies did not describe
persistence [26, 31]. In six studies [21, 23, 25, 26, 31, 32], the
effect of a single-component intervention was studied, while
nine studies [22, 24, 27–30, 33–35] studied a multicomponent
intervention.
Questionnaires and/or diaries (n = 8) [22, 23, 25, 27–31],
and pharmacist databases (n = 3) [21, 26, 33] were the most
common sources methods for data collection. Other methods
included patient records (n = 1) [35], empty drug boxes (n = 1)
[27], laboratory tests (n = 1) [26], collection of medication
during a consultation (n = 1) [32], and retrieved from the
PAADRN trial (n = 1) [24, 37]. In one study, the authors did
not report the method of data collection [34].
Patient education
Nine studies assessed the effects of patient education of which
were seven RCTs, one cohort study, and one observational
study [24, 25, 27–31, 34, 35]. In these nine studies, adherence
was used as an outcome [24, 25, 27–31, 34, 35], and in two
studies, persistence was also reported [27, 31]. Interventions
can further be classified into educational sessions (consisted
of meetings with 4–6 patients and a psychologist) (n = 2) [27,
30], provision of educational material (n = 8) [24, 25, 27,
29–31, 34, 35], and the use of a decision aid (n = 1) [28].
Educational material varied between providing information
booklets or flyers [24, 25, 27, 29–31, 34], providing DVDs
with visual information regarding the intervention, (treatment
of) osteoporosis, and how to discuss this with the physician
[25], or a decision aid which included the personal risk on a
fracture [28]. In seven studies, education was combined with
counseling. The way and the intensity of patient counseling
varied from offering patients advice and recommendation
concerning the educational material [35] to up to four tele-
phonic follow-up calls combined with 4 group sessions in
12 months [30].
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Fig. 1 PRIMSA flow chart
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Table 1 The main study characteristics









1 Roux et al. Canada 2013 Secondary
care
RCT Aged ≥ 50 years with a fragility fracture I1 370
I2 311
C 200





2 Tüzün et al. Turkey 2013 Secondary
care
RCT Women aged between 45 and
75 years with postmenopausal






3 Bianchi et al. Italy 2015 Secondary
care
RCT Females aged 45–80 years,
diagnosed with post-menopausal
osteoporosis, receiving a first pre-




12 months Hospital staff
(physicians
and nurses)
4 Cram et al. USA 2016 Secondary
care







5 Gonnelli et al. Italy 2016 Secondary
care
RCT Osteoporotic woman aged ≥ 50 receiving
a prescription of an oral osteoporosis
medication for the first time
I 402
C 414
12 months Physician NS
6 LeBlanc et al. Australia 2016 Secondary
care
RCT English speaking woman aged ≥ 50 with




















8 Beaton et al. Canada 2017 Secondary
care
Cohort study Fragility fracture patients (≥ 50 years;




12 months A trained
coordinator
9 Danila et al. USA 2018 Secondary
care
RCT Women with self-reported fracture histo-





























osteoporosis aged 55 to 85 years,
eligible for anti-osteoporosis treat-
ment
I/C 4481 26 weeks NR
12 Tamechika et al. Japan 2018 Secondary
care
RCT Systemic rheumatic diseases aged











RCT Women aged > 50 years, a documented
osteoporosis-related fracture










RCT Female aged ≥ 50 years attending the




12 months FLS nurse
Interdisciplinary collaboration
15 Ganda et al. Australia 2014 Primary and
second-
ary care
RCT Aged > 45 years and sustained a




24 months FLS staff (NS)
and PCP
I, intervention; C, control group; NR, not reported; NS, not specified
1 Patients were their own control
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A significant effect on medication adherence was observed
in two of the nine studies, both multicomponent interventions
[29, 34]. One study combining patient education, counseling,
blood tests, BMD test prescription, and follow-up phone calls
resulted in an increase in adherence between 40 and 53% in
the intervention groups, compared with 19% in usual care and
odds ratios of 2.55–5.07 [29]. When an educational program
was combined with a referral to an endocrinologist for a con-
sultation, implementation rates improved significantly com-
pared with usual care (for females, intervention 95% vs. con-
trol 90%; for males, intervention 97% vs. control 82%; both
p = 0.04) [34]. Seven studies were unable to significantly af-
fect adherence to osteoporosis medications or provide a sig-
nificance level with their results [24, 25, 27, 28, 30, 31, 35].
Albeit, of these studies, the single-component interventions
included solely providing educational material [25, 31]. The
multicomponent interventions included providing patients the
DXA score combined with educational material [24], identi-
fication of patients at risk for osteoporosis combined with
educational material [35] providing a decision aid or FRAX
results combined with patient counseling [28], and the more
extensive provision of educational material, an alarm clock,
phone calls, and patient counseling/group meetings [27, 30].
In none of the included studies, a significantly positive effect
on persistence was described.
Drug regimen
Three studies evaluated the effect of alterations in drug regi-
men compared with usual care. Of these studies, two were
RCTs and one was an observational study [23, 32, 33].
Adherence (not further defined) was the primary outcome in
one study [23], while the two other studies focused on both
implementation and discontinuation [32, 33]. The studies con-
cerned single-component interventions as either offering pa-
tients a choice of flexible dosing regimen [32] or switching to
an alternative drug with longer dosing intervals [23], or mul-
ticomponent interventions of a combination of signaling of
non-adherence, and offering alternative medication combined
with counseling [33]. None of the studies resulted in a signif-
icant improvement of adherence/implementation. There was a
significant positive effect on discontinuation in two studies. In
one study, a choice of flexible dosing regimen compared with
usual care resulted in 86% vs. 79% no discontinuation (p =
0.03) [32], and the combination of signaling of non-adherence
with offering alternative medication combined with counsel-
ing compared with usual care led to no discontinuation 84%
vs. 72% (p < 0.01) [33].
Monitoring and supervision
Monitoring and supervision was investigated in two RCT
studies [22, 26]. Implementation and discontinuation to
osteoporosis medications were the outcome in one study
[22] and persistence in the other [26]. In both studies, patients
frequently received telephone calls as a reminder to take their
medication as prescribed, compared with usual care. In one
study, this was a multicomponent intervention, where the
phone calls were combined with patient counseling [22].
There was a positive effect on both implementation and dis-
continuation in one study with increased implementation rates
of 65% vs. 33% (p < 0.01) and non-discontinuation rates of
73% vs. 51% (p < 0.01) in the intervention group [22].
Persistence was not significantly affected [26].
Interdisciplinary collaboration
Finally, the influence of setting of care was assessed in one
RCT study, with longer term implementation of osteoporosis
medications as outcome [21]. During this single-component
study [21], patients, in whom anti-osteoporosis medication
was initiated at the Fracture Liaison Service (FLS), were either
allocated after 3 months to further follow up in the FLS (usual
care) or transferred to the principal care provider (PCP). After
24 months, there was no difference between the groups in
terms of implementation of anti-osteoporosis medications.
Quality assessment
The risk of bias was assessed with the RoB 2 or ROBINS-I
tool [17, 18]. The overall risk of bias of the included studies
varied from low to high/serious, increased risk of bias con-
cerned missing outcome data and selection of participants.
The results are presented in Appendix 2.
The quality of the three observational studies and twelve
RCTs was assessed with the STROBE tool [19] and with the
CONSORT tool [38], respectively. Overall, the quality of the
studies was variable and moderate. The results are presented
in Appendix 3. In general, the setting, eligibility criteria, and
the rationale were described well in the observational studies
[33–35]. However, sensitivity analysis, handling of missing
data, and the sample size calculation were absent in all three
studies. The sources of data for each variable fully were only
described in one study [35]. The RCTs were sufficient when
considering abstracts, eligibility criteria of the participants,
and the statistical analysis. One study reported changes which
occurred after the trial commenced [28]. None of the studies
reported any harms and methods of randomization, and allo-
cations were poorly described. Sources of funding were not
reported in one study [31]. In none of the studies, the inter-
ventions or data were blinded for the patient, physician, or
analyst.
There was no evident difference regarding the risk of bias
or study quality, when considering the different types of inter-
ventions or between single or multicomponent interventions.
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Discussion
For this updated review, 15 studies and 19 comparisons in
which interventions to improve adherence and persistence to
osteoporosis medications were assessed. Interventions includ-
ed patient education, monitoring and supervision, change in
drug regimen combined with patient support, and interdisci-
plinary collaboration.
Different approaches for patient education (combined with
counseling) were the most studied interventions, but the effect
on adherence was limited. Only two out of nine studies report-
ed significant improvements on implementation and discon-
tinuation [29, 34], and none of the interventions reported a
positive effect on persistence. Change in drug regimen, com-
bined with patient support [23, 32, 33], did not result in a
positive effect on implementation. Furthermore, a significant-
ly positive effect on discontinuation to osteoporosis medica-
tions was sorted when patients were offered a choice of flex-
ible dosing regime and a combination of signaling of non-
adherence with offering alternative medication combined with
counseling. There was a notable difference in patient partici-
pation and involvement; if the patient was counseled or of-
fered participation in the choice regarding the decision
concerning drug regimen, there was an improvement in no
discontinuation [32, 33], in contrast to no improvement in
adherence when the patient was not involved [23]. This im-
plicates that patient involvement is an important factor to im-
prove medication persistence while employing flexible dosing
regimen. Also, since there was no effect on implementation,
but an effect on discontinuation, it seems change in drug reg-
imen is only useful for patients already using osteoporosis
medications. Monitoring and supervision were shown to have
a positive effect on both implementation and discontinuation,
but only in one study. In this study, patients were offered
counseling, and not solely monitored or supervised [22].
Finally, there was no difference in terms of persistence to
osteoporosis medications when patients were either allocated
to the regular FLS for 24 months (usual care) or transferred to
the principal care provider (PCP) after 3 months for a follow-
up of 21 months [21]. Although this did not lead to an im-
provement in medication persistence, it also did not lead to a
decrease. This implicates that the role of the rheumatologist
can partially be replaced by other physicians making the treat-
ment more flexible.
Compared with the previous SLR, there was a notable dif-
ference in interventions; in the included articles for this re-
view, there was more emphasis on patient involvement,
counseling, and shared decision-making, hence multicompo-
nent interventions, instead of solely patient information/
education or supervision each (single component interven-
tion), and there was a larger variation of healthcare profes-
sionals involved in conduction of these interventions. Earlier
studies described that patient education had the potential to
increase adherence, but new research published since the pre-
vious SLR could not confirm this, despite some reasonable
effect size, and the effect of solely patient education seems
limited [39–41]. Improvement is only expected when it is
combined with counseling. Similarities are found when com-
paring strategies in other chronic diseases, as diabetes; educa-
tion is seen as the cornerstone which is integrated in each
intervention strategy combined with involvement of the
healthcare provider and patient, a so-called combined
educational-behavioral strategy [42]. Compared with the pre-
vious SLR, an improvement in the quality of studies is ob-
served. Of the fifteen included studies, the majority were ran-
domized controlled trials, mostly of reasonable quality.
However, there was heterogeneity in methodology and
(reporting of) results, similar to the previous SLR. Risk of bias
was variable, from low to high/serious. As in the previous
SLR, almost all studies used adherence as outcome, and per-
sistence was less frequently used. The definitions which were
used for adherence and persistence still varied greatly; for
instance, we found twelve different descriptions of adherence.
These findings show that the taxonomy for describing and
defining adherence to medications by Vrijens et al. is not fully
implemented yet [16], as was also concluded in the previous
SLR.
There was an effect of a change in drug regimen, as report-
ed in earlier studies, in which flexible dosing regimens were
effective in increasing adherence, regardless of the level of
patient involvement [10]. However, multicomponent inter-
ventions, where a change of drug regimen is combined with
counseling, also led to an increase of no discontinuation
levels. In the field of neurology, especially migraine/chronic
headache, it is emphasized that drug regimens concerning
preventive medication should be tailored to lifestyle, to in-
crease adherence, thus also focusing on multicomponent in-
tervention [43].
Interdisciplinary collaboration was described successful
when improving adherence in other studies within the field
of osteoporosis or in other diseases [44, 45], contrary to our
findings. However, to lift the burden on medical specialists,
interdisciplinary collaboration could be of added value, since
there was no decrease of persistence either [46–48].
The currently available data on adherence and persistence
to osteoporosis medications have several limitations. First, the
available data was mostly self-reported, introducing social
desirability and recall bias, or may not be true values due to
the use of prescription data and time until last prescription
refill [6]. In addition, this resulted also in an increased risk
of bias of missing outcome data.
Second, in none of the studies, the intervention or data were
blinded for the patient, physician, or analyst. While this is not
always possible, especially for patients, it could result in con-
firmation bias and selection bias. Third, the follow-up time
was limited to a maximum of 24 months; hence, osteoporosis
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is a chronic disease; this could be of influence on the long-
term results of adherence and persistence.
There were strengths and potential issues in relation to the
methodology and execution of this review. The search was
designed with the help of an expert library specialist. Article
selection, data extraction, and quality appraisal were conduct-
ed by at least two researchers. Furthermore, the review was
executed in accordance with the PRISMA statement.
Although we found 15 new adherence intervention studies,
the conclusions on adherence interventions remain blurred,
and still no clear recommendations regarding interventions
to improve medication adherence and persistence can be de-
rived from our review. Moreover, we recognized the same
limitations with regard to quality and thus interpretation, com-
parison, or meta-analyses. In other words, we confirmed var-
iability in definition and measurement of adherence outcome,
challenges to classify adherence interventions, and limitations
in design related to blinding of patients and/or physicians,
sensitivity analysis, handling of missing data, and often sam-
ple calculations. Notwithstanding, we feel our review does
provide added value by pointing to the direction on which
future research should focus, namely, multicomponent inter-
ventions with active patient involvement.
With regard to the classification of interventions into four
categories, non-homogenous groups are possibly not compa-
rable with other studies/reviews. The ABC taxonomy by
Vrijens et al. [16] was used for organizing and comparing data
for this review, resulting in the use of the terms adherence,
subdivided in initiation, implementation and discontinuation,
and persistence, which sometimes differed compared with the
terms used in the original articles. Also, the influence of the
health system (e.g., co-payments, reimbursement, and differ-
ence in primary and secondary care), which differs per coun-
try, was not considered [9]. In a recent ESCEO paper, different
recommendations to improve medication adherence and per-
sistence were drafted by an international working group [12].
These include patient education and counseling, improving
patient interaction and shared-decision making, and dose sim-
plification such as the use of gastro-resistant risedronate tab-
lets that could be taken after breakfast. In addition, the ESCEO
working group recognized the need for more evidence and
high-quality research and provides recommendations for fur-
ther research in the field.
In conclusion, this updated review suggests that improving
adherence and persistence to osteoporosis medications re-
mains a complex and challenging issue, and no clear recom-
mendations can unfortunately be derived from it. Patient edu-
cation, monitoring and supervision, change in drug regimen
combined with patient support, and interdisciplinary collabo-
ration were shown to have some effect on either adherence or
persistence but only in some of the studies. However, interest-
ingly, multicomponent interventions with active patient in-
volvement were the most effective interventions when aiming
to increase adherence and/or persistence to osteoporosis med-
ications. It would thus be important to design appropriate
multicomponent interventions and to critically evaluate them
with means of well-designed randomized controlled trials,
ideally with longer follow-up.
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Appendix 2
Table 5 Risk of bias (the Risk Of
Bias In Non-randomized Studies -
of Interventions (ROBINS-I) as-
sessment tool)
Author Seuffert Beaton Stuurman-
BiezeRisk of Bias
Bias due to confounding Low Low Low
Bias in selection of participants into the study Low Low Serious
Bias in classification of interventions Low Low Serious
Bias due to deviations from intended interventions Low Low Low
Bias due to missing data Moderate Moderate Moderate
Bias in measurement of outcomes Low Low Low
Bias in selection of the reported result Low Low Low
Overall risk of bias Moderate Moderate Serious
Table 6 Quality of the selected studies
Consort checklist Articles
Consort Item Roux Tuzun Bianchi
Title and abstract
1a Identification as a randomized trial in the title - + -
1b Structured summary of trial design, methods, results, and conclusions. + + +
Introduction
2a Scientific background and explanation of rationale + + +
2b Specific objectives or hypotheses + + +
Methods
3a Description of trial design (such as parallel, factorial) including allocation ratio + + +
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons - - +/-
4a Eligibility criteria for participants + + +
4b Settings and locations where the data were collected + +/- +
5 The interventions for each group with sufficient details to allow replication, including how and
when they were actually administered
+ + +
6a Completely defined pre-specified primary and secondary outcome measures, including how and
when they were assessed]
+ + +
6b Any changes to trial outcomes after the trial commenced, with reasons - N/a N/a
7a How sample size was determined + - -
7b When applicable, explanation of any interim analyses and stopping guidelines - - N/A
8a Method used to generate the random allocation sequence - + +
8b Type of randomization; details of any restriction (such as blocking and block size) - + +
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered
containers), describing any steps taken to conceal the sequence until interventions were
assigned
- + +/-
10 Who generated the random allocation sequence, who enrolled participants, and who assigned
participants to interventions
- - -
11a If done, who was blinded after assignment to interventions (for example, participants, care
providers, those assessing outcomes) and how
- - N/a
11b If relevant, description of the similarity of interventions + + +
12a Statistical methods used to compare groups for primary and secondary outcomes + + +
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses - - +
Results
13a For each group, the numbers of participants who were randomly assigned, received intended
treatment, and were analyzed for the primary outcome
+ + +
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Table 6 (continued)
13b For each group, losses and exclusions after randomization, together with reasons - - -
14a Dates defining the periods of recruitment and follow-up + - -
14b Why the trial ended or was stopped - - -
15 A table showing baseline demographic and clinical characteristics for each group - + +/-
16 For each group, number of participants (denominator) included in each analysis and whether the
analysis was by original assigned groups
+ + -
17a For each primary and secondary outcome, results for each group, and the estimated effect size and
its precision (such as 95% confidence interval)
+ + +/-
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended + + -
18 Results of any other analyses performed, including subgroup analyses and adjusted analyses,
distinguishing pre-specified from exploratory
- - N/a




20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of
analyses
+ + +/-
21 Generalisability (external validity, applicability) of the trial findings + +/- +/-





23 Registration number and name of trial registry + - +
24 Where the full trial protocol can be accessed, if available + - +
25 Sources of funding and other support (such as supply of drugs), role of funders + + +
Consort checklist Articles
Consort Item Cram Gonelli Leblanc
Title and abstract
1a Identification as a randomized trial in the title + - +
1b Structured summary of trial design, methods, results, and conclusions. + + +
Introduction
2a Scientific background and explanation of rationale + + +
2b Specific objectives or hypotheses + + +
Methods
3a Description of trial design (such as parallel, factorial) including allocation ratio + + +
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons N/a - -
4a Eligibility criteria for participants + + +/-
4b Settings and locations where the data were collected + +/- +
5 The interventions for each group with sufficient details to allow replication, including how and
when they were actually administered
+ -/+ +
6a Completely defined pre-specified primary and secondary outcome measures, including how and
when they were assessed]
+ + +
6b Any changes to trial outcomes after the trial commenced, with reasons N/a N/a N/a
7a How sample size was determined + - _
7b When applicable, explanation of any interim analyses and stopping guidelines N/a - -
8a Method used to generate the random allocation sequence + - +
8b Type of randomization; details of any restriction (such as blocking and block size) + - +
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered
containers), describing any steps taken to conceal the sequence until interventions were assigned
+ - +
10 Who generated the random allocation sequence, who enrolled participants, and who assigned
participants to interventions
+/- - -
11a If done, who was blinded after assignment to interventions (for example, participants, care
providers, those assessing outcomes) and how
+ - +
11b If relevant, description of the similarity of interventions N/a + +
12a Statistical methods used to compare groups for primary and secondary outcomes + + +
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses - - -
Results
13a For each group, the numbers of participants who were randomly assigned, received intended
treatment, and were analyzed for the primary outcome
+ + +
13b For each group, losses and exclusions after randomization, together with reasons +/- - +
14a Dates defining the periods of recruitment and follow-up - +/- +
14b Why the trial ended or was stopped - - -
15 A table showing baseline demographic and clinical characteristics for each group + - -
16 For each group, number of participants (denominator) included in each analysis and whether the
analysis was by original assigned groups
+/1 + +
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Table 6 (continued)
17a For each primary and secondary outcome, results for each group, and the estimated effect size and
its precision (such as 95% confidence interval)
- + +
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended N/a + +
18 Results of any other analyses performed, including subgroup analyses and adjusted analyses,
distinguishing pre-specified from exploratory
N/a - -




20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of
analyses
+ + +
21 Generalisability (external validity, applicability) of the trial findings +/- + +




23 Registration number and name of trial registry + - +
24 Where the full trial protocol can be accessed, if available + - +
25 Sources of funding and other support (such as supply of drugs), role of funders + - +
Consort checklist Articles
Consort Item Danila Stuurman-Bieze Oral
Title and abstract
1a Identification as a randomized trial in the title + - +/-
1b Structured summary of trial design, methods, results, and conclusions. + + +
Introduction
2a Scientific background and explanation of rationale + +/- +
2b Specific objectives or hypotheses + + +
Methods
3a Description of trial design (such as parallel, factorial) including allocation ratio + + +
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons N/a N/a N/a
4a Eligibility criteria for participants + + +
4b Settings and locations where the data were collected + + +/-
5 The interventions for each group with sufficient details to allow replication, including how and
when they were actually administered
+ +/- +
6a Completely defined pre-specified primary and secondary outcome measures, including how and
when they were assessed]
+ + +/-
6b Any changes to trial outcomes after the trial commenced, with reasons N/a N/a N/a
7a How sample size was determined + - -
7b When applicable, explanation of any interim analyses and stopping guidelines - N/a N/a
8a Method used to generate the random allocation sequence + - +
8b Type of randomization; details of any restriction (such as blocking and block size) + - +
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered
containers), describing any steps taken to conceal the sequence until interventions were assigned
+ - -
10 Who generated the random allocation sequence, who enrolled participants, and who assigned
participants to interventions
+ - +/-
11a If done, who was blinded after assignment to interventions (for example, participants, care
providers, those assessing outcomes) and how
+ N/a N/a
11b If relevant, description of the similarity of interventions + N/a N/a
12a Statistical methods used to compare groups for primary and secondary outcomes + + +
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses + - -
Results
13a For each group, the numbers of participants who were randomly assigned, received intended
treatment, and were analyzed for the primary outcome
+ + +
13b For each group, losses and exclusions after randomization, together with reasons + + +
14a Dates defining the periods of recruitment and follow-up + + -
14b Why the trial ended or was stopped N/a + -
15 A table showing baseline demographic and clinical characteristics for each group + + -
16 For each group, number of participants (denominator) included in each analysis and whether the
analysis was by original assigned groups
+ - -
17a For each primary and secondary outcome, results for each group, and the estimated effect size and
its precision (such as 95% confidence interval)
+ + +
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended + + +
18 Results of any other analyses performed, including subgroup analyses and adjusted analyses,
distinguishing pre-specified from exploratory
+ N/a -
19 All important harms or unintended effects in each group (for specific guidance see CONSORT for
harms)
- - -
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Table 6 (continued)
Discussion
20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of
analyses
+ +/- +/-
21 Generalisability (external validity, applicability) of the trial findings - + +/-




23 Registration number and name of trial registry + - -
24 Where the full trial protocol can be accessed, if available + - -








1a Identification as a randomized trial in the title + -
1b Structured summary of trial design, methods, results, and conclusions. + +
Introduction
2a Scientific background and explanation of rationale + +/-
2b Specific objectives or hypotheses + +
Methods
3a Description of trial design (such as parallel, factorial) including allocation ratio + -
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons - N/a
4a Eligibility criteria for participants + +
4b Settings and locations where the data were collected + +/-
5 The interventions for each group with sufficient details to allow replication, including how and
when they were actually administered
+ +
6a Completely defined pre-specified primary and secondary outcome measures, including how and
when they were assessed]
+ +
6b Any changes to trial outcomes after the trial commenced, with reasons - N/a
7a How sample size was determined + +
7b When applicable, explanation of any interim analyses and stopping guidelines - N/a
8a Method used to generate the random allocation sequence - -
8b Type of randomization; details of any restriction (such as blocking and block size) - -
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered
containers), describing any steps taken to conceal the sequence until interventions were assigned
- -
10 Who generated the random allocation sequence, who enrolled participants, and who assigned
participants to interventions
- -
11a If done, who was blinded after assignment to interventions (for example, participants, care
providers, those assessing outcomes) and how
- N/a
11b If relevant, description of the similarity of interventions + N/a
12a Statistical methods used to compare groups for primary and secondary outcomes + +
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses - -
Results
13a For each group, the numbers of participants who were randomly assigned, received intended
treatment, and were analysed for the primary outcome
+ +
13b For each group, losses and exclusions after randomisation, together with reasons +/- +/-
14a Dates defining the periods of recruitment and follow-up + -
14b Why the trial ended or was stopped - -
15 A table showing baseline demographic and clinical characteristics for each group - +
16 For each group, number of participants (denominator) included in each analysis and whether the
analysis was by original assigned groups
+ -
17a For each primary and secondary outcome, results for each group, and the estimated effect size and
its precision (such as 95% confidence interval)
+ +
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended + +
18 Results of any other analyses performed, including subgroup analyses and adjusted analyses,
distinguishing pre-specified from exploratory
- -




20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of
analyses
+ +
21 Generalisability (external validity, applicability) of the trial findings + +
22 + +
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Table 6 (continued)
Interpretation consistent with results, balancing benefits and harms, and considering other
relevant evidence
Other information
23 Registration number and name of trial registry + -
24 Where the full trial protocol can be accessed, if available + -




Strobe item Beaton Seuffert
Title and abstract
1a Indicate the study’s design with a commonly used term in the title or the abstract + +




2 Explain the scientific background and rationale for the investigation being reported + +
3 State specific objectives, including any pre-specified hypotheses +/- +/-
Methods
4 Present key elements of study design early in the paper + +
5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure,
follow-up, and data collection
+ +
6a Give the eligibility criteria, and the sources and methods of selection of participants. Describe
methods of follow-up
+/- +/-
6b For matched studies, give matching criteria and number of exposed and unexposed N/a -
7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers.
Give diagnostic criteria, if applicable
+/- +/-
8 For each variable of interest, give sources of data and details of methods of assessment
(measurement). Describe comparability of assessment methods if there is more than one group
+ -
9 Describe any efforts to address potential sources of bias - -
10 Explain how the study size was arrived at - -
11 Explain how quantitative variables were handled in the analyses. If applicable, describe which
groupings were chosen and why
+ +/-
12a Describe all statistical methods, including those used to control for confounding + +/-
12b Describe any methods used to examine subgroups and interactions +/- N/a
12c Explain how missing data were addressed - -
12d Cohort study—If applicable, explain how loss to follow-up was addressed
Case-control study—If applicable, explain how matching of cases and controls was addressed
Cross-sectional study—If applicable, describe analytical methods taking account of sampling
strategy
- -
12e Describe any sensitivity analyses - -
Results
13a Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined
for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
+/- +/-
13b Give reasons for non-participation at each stage - -
13c Consider use of a flow diagram + N/a
14a Give characteristics of study participants (eg demographic, clinical, social) and information on
exposures and potential confounders
+/- +/-
14b Indicate number of participants with missing data for each variable of interest - -
14c Cohort study—Summarise follow-up time (eg, average and total amount) + +
15 Cohort study—Report numbers of outcome events or summary measures over time - +
Case-control study—Report numbers in each exposure category, or summary measures of
exposure
N/a N/a
Cross-sectional study—Report numbers of outcome events or summary measures N/a N/a
16a Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision
(eg, 95% confidence interval). Make clear which confounders were adjusted for and why they
were included
- -
16b Report category boundaries when continuous variables were categorized - +
16c If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time
period
N/a N/a
17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses - -
Discussion
18 Summarise key results with reference to study objectives + +
19 Discuss limitations of the study, taking into account sources of potential bias or imprecision.
Discuss both direction and magnitude of any potential bias
+ +
20 + +
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Table 6 (continued)
Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of
analyses, results from similar studies, and other relevant evidence
21 Discuss the generalizability (external validity) of the study results - -
Other information
22 Other funding + -
Consort checklist Articles




1a Identification as a randomized trial in the title - +
1b Structured summary of trial design, methods, results, and conclusions. + +
Introduction
2a Scientific background and explanation of rationale + +
2b Specific objectives or hypotheses + +
Methods
3a Description of trial design (such as parallel, factorial) including allocation ratio +/- +
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons N/a N/a
4a Eligibility criteria for participants + +
4b Settings and locations where the data were collected +/- +
5 The interventions for each group with sufficient details to allow replication, including how and
when they were actually administered
+ +
6a Completely defined pre-specified primary and secondary outcome measures, including how and
when they were assessed]
+/- +
6b Any changes to trial outcomes after the trial commenced, with reasons N/a N/a
7a How sample size was determined + +
7b When applicable, explanation of any interim analyses and stopping guidelines - N/a
8a Method used to generate the random allocation sequence + +
8b Type of randomization; details of any restriction (such as blocking and block size) + +
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered
containers), describing any steps taken to conceal the sequence until interventions were assigned
- +
10 Who generated the random allocation sequence, who enrolled participants, and who assigned
participants to interventions
+/- +/-
11a If done, who was blinded after assignment to interventions (for example, participants, care
providers, those assessing outcomes) and how
- N/a
11b If relevant, description of the similarity of interventions + N/a
12a Statistical methods used to compare groups for primary and secondary outcomes + +
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses + +
Results
13a For each group, the numbers of participants who were randomly assigned, received intended
treatment, and were analysed for the primary outcome
+ +
13b For each group, losses and exclusions after randomisation, together with reasons + +/-
14a Dates defining the periods of recruitment and follow-up + -
14b Why the trial ended or was stopped N/a -
15 A table showing baseline demographic and clinical characteristics for each group +/- +
16 For each group, number of participants (denominator) included in each analysis and whether the
analysis was by original assigned groups
+ -
17a For each primary and secondary outcome, results for each group, and the estimated effect size and
its precision (such as 95% confidence interval)
+ +
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended + +
18 Results of any other analyses performed, including subgroup analyses and adjusted analyses,
distinguishing pre-specified from exploratory
+ +




20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of
analyses
+ +
21 Generalisability (external validity, applicability) of the trial findings +/- +/-




23 Registration number and name of trial registry + +
24 Where the full trial protocol can be accessed, if available - +
25 Sources of funding and other support (such as supply of drugs), role of funders + -
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Appendix 3
Open Access This article is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License, which permits
any non-commercial use, sharing, adaptation, distribution and
reproduction in any medium or format, as long as you give appropriate
credit to the original author(s) and the source, provide a link to the
Creative Commons licence, and indicate if changes were made. The
images or other third party material in this article are included in the
article's Creative Commons licence, unless indicated otherwise in a
credit line to the material. If material is not included in the article's
Creative Commons licence and your intended use is not permitted by
statutory regulation or exceeds the permitted use, you will need to
obtain permission directly from the copyright holder. To view a copy of
this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
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